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OBJECTIVES The purpose of this paper is to examine the incidence and determinants of permanent
complete heart block (CHB) after nonsurgical septal reduction therapy (NSRT), and to
evaluate the clinical impact of permanent pacemaker (PPM) placement.
BACKGROUND Nonsurgical septal reduction therapy with ethanol improves the clinical and hemodynamic
parameters in patients with symptomatic hypertrophic obstructive cardiomyopathy. Complete
heart block is a common complication after NSRT.
METHODS The database of 261 consecutive patients who underwent NSRT at Baylor College of
Medicine was reviewed. Clinical variables that were considered as possible determinants for
CHB after NSRT were: age, gender, New York Heart Association (NYHA) functional class,
left ventricular outflow tract (LVOT) gradient at rest or with provocation, septal thickness,
and baseline exercise duration. For electrocardiographic (ECG) variables, the presence of
first-degree atrioventricular (AV) block, bifascicular block, left bundle branch block, atrial
fibrillation, and left ventricular hypertrophy were analyzed. In addition, the volume of ethanol
injected, the method of administration of ethanol (i.e., bolus vs. slow injection [over 30 to 60
s]), number of septal arteries occluded, use of myocardial echocardiography, and infarct size
as determined by peak creatine kinase level.
RESULTS Of 261 consecutive patients, 37 had PPM or automatic implantable cardiac defibrillator
placed before NSRT. Of the remaining 224 patients, 31 (14%) developed CHB after the
procedure. Multivariate logistic regression analysis showed that female gender (odds ratio
[OR] 4.3; p  0.02), bolus injection of ethanol (OR 51; p  0.004), injecting more than one
septal artery (OR 4.6; p  0.016), the presence of left bundle branch block (OR 39; p 
0.002), and first-degree AV block (OR 14; p  0.001) on the baseline ECG are independent
predictors of CHB after NSRT. Patients requiring PPM placement had a similar improve-
ment in their NYHA functional class, septal thickness reduction, LVOT gradient reduction,
and improvement of exercise capacity when compared with patients who did not require
pacing.
CONCLUSIONS Multiple demographic, electrocardiographic, and technical factors seem to increase the risk of
CHB after NSRT. Patients with CHB after NSRT derive similar clinical and hemodynamic
benefit to patients who did not require permanent pacing. (J Am Coll Cardiol 2003;42:
296–300) © 2003 by the American College of Cardiology Foundation
Hypertrophic obstructive cardiomyopathy (HOCM) is
characterized by left ventricular hypertrophy and dynamic
left ventricular outflow tract (LVOT) obstruction (1,2).
Nonsurgical septal reduction therapy with ethanol (NSRT)
has been shown to improve symptoms and LVOT obstruc-
tion (3–9). We and others have reported on the clinical
outcome and the associated complications with this proce-
dure (4–10). Specifically, complete heart block (CHB) has
been reported to occur transiently or permanently in up to
50% of the treated patients (5,6,10,15). The incidence of
permanent pacemaker (PPM) requirement varies among
different studies, and the determinants of this complication
as well as its clinical impact at follow-up are not yet
completely known.
Therefore, the purpose of this study is to identify the
determinants of CHB, and its clinical impact after NSRT.
METHODS
The technique of NSRT has been previously published (6).
The database of 261 consecutive patients who underwent
the procedure at Baylor College of Medicine was reviewed.
In brief, only patients with drug-resistant symptoms of
dyspnea (New York Heart Association [NYHA] functional
class III or IV), or syncope underwent NSRT. All patients
were evaluated by echocardiography before and after the
procedure. All patients had a septal-to-posterior wall thick-
ness ratio of at least 1.3 and a resting LVOT gradient 30
mm Hg. Patients with classic symptoms, systolic anterior
motion of the anterior mitral leaflet, and a resting LVOT
gradient 30 mm Hg were provoked with up to 15
g/kg/min of dobutamine (mean 10  3 g/kg/min), and
they were considered candidates for this treatment if their
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dobutamine-provoked gradient exceeded 60 mm Hg (n 
41).
The study was approved by the Institutional Review
Board of Baylor College of Medicine, and written informed
consent was obtained from all patients. On the day of the
procedure, an electrocardiogram (ECG) was performed.
The ECG data were collected, reviewed, and analyzed, and
blood was collected for baseline creatine kinase (CK) mea-
sured in international units. A temporary pacemaker was
placed in all patients except for those who already had a
PPM in place. Two-dimensional echocardiography and
Doppler was done at baseline and during the procedure. A
6F, 7F, or 8F guiding catheter was engaged in the left main
coronary artery, and a 2.5  9-mm Ranger or Maverick
balloon catheter (Scimed, Minneapolis, Minnesota) was
advanced over a 0.014-inch wire into the target septal
perforator artery or arteries. In all except 10 patients,
myocardial contrast was injected through the balloon lumen
to delineate the area to be infarcted. One to 3 cc (mean 2.4
 0.3 cc) of ethanol were injected into the septal artery or
arteries, which supplied the culprit septal segments, and left
in place for 5 min. Patients who remained in CHB 72 h
after the procedure underwent permanent dual chamber
pacemaker placement. Patients stayed in the hospital for a
mean of 3.2  0.5 days. Follow-up was completed as
previously described for up to four years.
Predictors of PPM requirement. The following clinical
variables were considered in the analysis: age, gender,
NHYA functional class, LVOT gradient at rest or with
provocation, septal thickness, and baseline exercise duration.
For ECG variables, the presence of first-degree atrioven-
tricular (AV) block, bifascicular block, left bundle branch
block, atrial fibrillation, and left ventricular hypertrophy
were analyzed. In addition, the volume of ethanol injected,
the method of administration of ethanol (i.e., bolus vs. slow
injection [over 30 to 60 s]), number of septal arteries
occluded, use of myocardial echocardiography contrast
(MCE), and infarct size as determined by peak CK level.
To determine the clinical impact of permanent pacing
after NSRT, the group of patients who needed permanent
pacing after NSRT was compared with all the remaining
HOCM patients who were not pacemaker-dependent after
the procedure. In addition, we identified a control group
that matched the pacemaker group with respect to age,
baseline LVOT gradient, and follow-up period but did not
need permanent pacing.
Statistical analysis. Data are presented as mean  SD.
The two-sample unpaired Student t test was used to
compare the outcome variables between the pacemaker-
dependent group and the other group. Logistic regression
was applied for the prediction of CHB. A p value of 0.05
was considered significant.
RESULTS
Baseline characteristics. A total of 261 patients were
included in this analysis. The mean age was 51  6 years,
and 127 patients were women. The baseline NYHA score
was 2.7  0.5. The resting LVOT gradient was 62  28
mm Hg, and the average septal thickness was 2.0  0.4 cm.
Left ventricular ejection fraction was 71  7%. The peak
CK was 1,335  653 at 9 h after alcohol injection.
The baseline demographic, procedural, and clinical char-
acteristics of different subgroups of patients are shown in
Table 1. The ECG data before the procedure are shown in
Table 2. The prevalence of left bundle branch block was
more common in the group of patients who developed CHB
and subsequent permanent pacing.
Abbreviations and Acronyms
AV  atrioventricular
CHB  complete heart block
CK  creatine kinase
ECG  electrocardiogram/electrocardiographic
HOCM  hypertrophic obstructive cardiomyopathy
LVOT  left ventricular outflow tract
MCE  myocardial contrast echocardiography
NSRT  nonsurgical septal reduction therapy
NYHA  New York Heart Association
OR  odds ratio
PPM  permanent pacemaker
Table 1. Baseline Demographic, Procedural, and
Echocardiographic Characteristics of Patients Who Did and




(n  193) p Value
Age (yrs) 58  14 52  16 0.06
Female gender (%) 19 (59%) 81 (42%) 0.045
No MCE (%) 3 (10%) 3 (1.5%) 0.001
Bolus injection (%) 7 (23%) 5 (3%) 0.001
2 septals (%) 13 (42%) 49 (25%) 0.05
Ethanol (cc) 2.9  1.6 2.9  1.3 NS
LVOTG (mm Hg) 67  40 60  39 0.45
NYHA CHF class 2.85  0.5 2.65  0.6 0.25
IVS (cm) 2.06  0.43 2.04  0.5 0.80
EF % 74  7 73  6 0.87
Treadmill exercise time (s) 278  197 296  202 0.55
CHF  congestive heart failure; IVS  interventricular septal thickness (cm);
LVOTG  left ventricular outflow tract gradient (mm Hg); MCE  myocardial
contrast echocardiography; NS  non significant; NSRT  nonsurgical septal
reduction therapy; NYHA  New York Heart Association; PPM  permanent
pacemaker.
Table 2. Baseline ECG in Patients Who Required PPM Versus




(n  193) p Value
Normal ECG 16% 27% NS
LVH by voltage 39% 45% NS
First-degree AV block 19% 5% 0.059
LBBB 13% 1.5% 0.001
Bifascicular block 6% 2% NS
Atrial fibrillation 0 4% NS
AV  atrioventricular; ECG  electrocardiogram; LBBB  left bundle branch
block; LVH left ventricular hypertrophy; NS not significant; PPM permanent
pacemaker.
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Incidence of pacemaker requirement. A total of 37
patients had a PPM or automated implantable cardiac
defibrillator in place before the procedure. Only six of them
were not paced on baseline ECG before the procedure. Of
the 224 patients who did not have a PPM before NSRT,
31(14%) required permanent pacing. All patients had their
PPMs implanted before discharge, except for one patient
who developed CHB one week after the procedure. A
higher incidence of permanent pacing was present in our
first group of 33 patients (33%) compared with the subse-
quent 191 patients in whom only 10% required permanent
pacing. Of note, MCE was not employed in the first 10
patients. Furthermore, ethanol was administrated as a bolus
injection (rather than slow delivery) in the first 17 patients.
There was no significant association between peak CK level
and the need for PPM (1,333  873 vs. 1,331  681; p 
0.99). Furthermore, when the CK level was adjusted to the
interventricular septal thickness, there was still no difference
between the two groups (629  345 vs. 669  567; p 
0.9).
Predictors of CHB after ablation. Multiple baseline and
procedure-related characteristics were studied to determine
their relationship to CHB. Table 3 shows the outcome of
the univariate analysis for predictors of occurrence of this
complication after NSRT. As shown, female gender (p 
0.045), lack of use of MCE (p  0.001), injecting ethanol
as a bolus instead of gradual injection (p  0.001), injecting
ethanol into more than one septal artery (p 0.05), and the
presence of left bundle branch block on the baseline ECG
(p 0.001) were all found to be significant determinants for
the development of CHB. The volume of ethanol injected
and the peak CK obtained after the procedure did not
predict AV block in this model. On multivariate analysis
(Table 4), female gender (odds ratio [OR] 4.3; p  0.02),
bolus injection of ethanol (OR 51; p  0.004), injecting
more than one septal artery (OR 4.6; p  0.016), first-
degree AV block on the baseline ECG (OR 14; p 0.001),
and the presence of left bundle branch block (OR 39; p 
0.002) were all significant predictors of CHB after NSRT.
Clinical impact of PPM requirement. At follow-up
(mean 24 19 months), 28 of the 31 patients who required
permanent pacing after the procedure remained in paced
rhythm and, of these patients, 25 were pacemaker-
dependent during treadmill exercise testing. As shown in
Table 5, when compared with patients (n  193) who did
not develop CHB, the 31 patients who were paced after the
procedure derived similar benefit from NSRT. Specifically,
77% of patients who required a PPM became  NYHA
functional class II for dyspnea compared with 67% of
patients without PPM (p  0.26). Sixty-one percent of
patients with PPM improved by 2 NYHA classes com-
pared with 43% of patients without PPM (p  0.06).
We then selected 31 nonpaced patients who were
matched for age, baseline LVOT gradient, and follow-up
duration to the 31 patients who were pacemaker-dependent
after NSRT. As seen in Table 6, baseline characteristics
were similar between the two matched groups. The group
with CHB had more septal arteries injected (1.45  0.5 vs.
1.17  0.38; p  0.023), and a larger number of patients
who (7 compared with 0) received bolus injection of
ethanol. As shown in Table 7, both groups had a similar
improvement in clinical and hemodynamic variables after
NSRT. Notably, 61% (19/31) of patients who required
PPM have improved by 2 NYHA dyspnea classes on
follow-up compared with 49% (15/31) of patients who did
not require a PPM (p  0.3). In addition, 77% (24/31) of
patients with PPM have become  NYHA functional class
II for dyspnea compared with 68% (21/31) of patients who
did not require a PPM (p  0.4).
DISCUSSION
Nonsurgical septal reduction therapy is currently performed
at multiple centers in the U.S. and Europe with a high
procedural success rate and an acceptable complication rate.
Many published reports have confirmed the persistent
improvement in symptoms, along with reduction in LVOT





(n  193) p Value
Age 55 yrs 18 (58%) 77 (40%) 0.06
Female gender (%) 19 (59%) 81 (42%) 0.045
No MCE (%) 3 (10%) 3 (1.5%) 0.001
Bolus injection (%) 7 (23%) 5 (3%) 0.001
1 septal artery (%) 13 (42%) 49 (25%) 0.05
LBBB (%) 4 (13%) 3 (1.5%) 0.001
First-degree AV block 6 (19%) 10 (5%) 0.059
LBBB  left bundle branch block; MCE  myocardial contrast echocardiography.
Other abbreviations as in Table 2.
Table 4. Multivariate Analysis for Prediction of PPM
Placement After NSRT
Odds Ratio 95% CI p Value
LBBB 39 3.6–416 0.002
2 septals injected 4.6 1.3–16 0.016
Bolus injection of ethanol 51 3.5–735 0.004
First-degree AV block 14 3–69 0.001
Female gender 4.3 1.3–15 0.02
CI  confidence interval. Other abbreviations as in Tables 2 and 3.
Table 5. Comparison of Clinical and Echocardiographic





n  193 p Value
NYHA class improvement 1.76  0.63 1.47  0.74 0.09
IVS reduction 0.82  0.67 0.56  0.54 0.063
% IVS reduction 37  20 27  26 0.003
Rest LVOTG reduction 56  42 40  37 0.07
Increase in exercise duration(s) 68  149 102  138 0.35
IVS  interventricular septal thickness; LVOTG  left ventricular outflow tract
gradient (mm Hg); NYHA  New York Heart Association. Other abbreviations as
in Tables 2 and 3.
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gradient and left ventricular remodeling in the
intermediate-term follow-up (8,10–12). The success rate of
NSRT was also comparable to that of surgical myectomy in
nonrandomized studies (13). Complete heart block is the
most commonly reported complication after NSRT; there-
fore, the overall results after NSRT can be further improved
by decreasing the incidence of CHB.
Nonsurgical septal reduction therapy results in several
changes in the AV and intraventricular conduction. In
general, first-degree AV block, right bundle branch block,
left anterior fascicular block, left bundle branch block, and
nonspecific intraventricular conduction delay have been
reported after NSRT. First-degree AV block is often
transient, and only 2% of patients develop permanent
first-degree AV block after one year (6,14). On the other
hand, right bundle branch block occurs in 60% to 100% of
patients and is more likely to be permanent (4,6,14).
However, the most serious conduction abnormality is CHB,
which develops transiently in up to two-thirds of patients
(4,10) or permanently in 0% to 25% according to different
series (4–6,9,10,15–18). The overall incidence in our series
is 14%. This number is much lower than what we have
initially reported with our first 33 patients (6). With
experience and modification of technique such as the use of
MCE and slow injection of alcohol, the incidence of CHB
requiring PPM decreased to 10% in the last 191 patients.
Thirty of the 31 patients had CHB immediately after the
ethanol injection. Only one patient returned with this
complication one week after the procedure. Most of the
patients remained paced at follow-up, both at rest and on
exercise.
Lack of conduction abnormality during transient occlu-
sion of septal arteries without ethanol has been proposed as
a potentially useful method in screening patients for devel-
oping CHB (17); however, subsequent studies showed
suboptimal predictability of this method in regard to reduc-
tion of LVOT gradient after the procedure (4).
Baseline conduction abnormalities have been suggested as
a risk factor for development of CHB (14). Using multi-
variate analysis, we have shown that the presence of left
bundle branch block and first-degree AV block on the
baseline ECG are associated with a higher incidence of
CHB. This finding is expected, knowing that more than
two-thirds of patients undergoing NSRT develop complete
right bundle branch block (6). Additional insult to a
previously diseased conduction system is more likely to
result in this complication.
Our analysis also revealed a gender difference in the
susceptibility of CHB. Female patients were at higher risk.
They tended to be older (55  17 years vs. 48  15 years)
had worse NYHA functional class, higher rest LVOT, and
thinner interventricular septum as compared with their male
counterparts. However, they also had a smaller infarct size
and CK level/interventricular septum ratio. Nevertheless,
after adjusting for all the baseline demographic, clinical,
ECG, and procedural characteristics, female gender still
predicted a higher risk for CHB.
In addition to baseline conduction disorders, certain
procedural techniques are associated with a higher propen-
sity for CHB such as the number of injected septal arteries,
(probably due to involvement of multiple sites of the
conduction pathway) and bolus injection of ethanol, which
deprives the operator of the ability to slow down or abort the
injection of ethanol in the face of a developing conduction
disorder. We believe that the concomitant technical changes
that occurred after our first 17 patients (use of MCE and
injecting ethanol slowly) accounted for the significant re-
duction in the incidence of CHB after NSRT. A repeat
analysis was done after we excluded the first 17 patients in
whom no MCE was used and ethanol was injected as a
bolus. By univariate analysis, older patients (55 years),
female gender, left bundle branch block, and first-degree
AV block continued to be significant determinants of CHB.
On univariate analysis, all except age55 years significantly
predicted CHB after NSRT.
The clinical impact of CHB has not been well studied.
Our data suggest that the development of CHB does not
compromise patients’ outcome after NSRT. However, more
prospective data is needed to verify that right ventricular
pacing does not reduce the potential benefit of NSRT, as
some recent studies have suggested that right ventricular
pacing may impair ventricular performance in the presence
of hypertrophy and failure, as compared with normal con-
duction or biventricular pacing.
In conclusion, our findings suggest that multiple factors
Table 6. Baseline Demographic and Echocardiographic




(n  31) p Value
Age (yrs) 58  14 57  14 0.83
Female gender 19 15 0.31
LVOTG resting 67  40 66  35 0.86
LVOTG provoked 102  43 90  29 0.73
NYHA CHF class 2.85  0.5 2.7  0.5 0.19
IVSD (cm) 2.06  0.43 2.07  0.57 0.67
EF (%) 74  7 73.6  7 0.9
Exercise time (s) 278  197 285  208 0.91
Peak CK (U/dl) 1,333  554 1,331  681 0.9
Ethanol volume (mm) 2.9  1.66 2.6  0.76 0.31
Number of septal arteries
injected
1.45  0.5 1.17  0.38 0.023
Ethanol bolus injection 7 0
CK  creative kinase; EF  ejection fraction. Other abbreviations as in Tables 1 and 5.
Table 7. Clinical and Echocardiographic Implication of PPM




(n  31) p Value
NYHA CHF class improvement 1.76  0.63 1.48  0.8 0.11
IVS reduction (cm) 0.82  0.67 0.5  0.7 0.08
Rest LVOTG reduction, mm Hg 56  42 39  45 0.06
Increase in exercise time (s) 68  149 132  116 0.13
Abbreviations as in Tables 1 and 5.
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may contribute to the development of CHB after NSRT.
Female gender and baseline conduction abnormalities seem
to increase the risk for this complication. Patients with
CHB after NSRT seem to derive similar clinical and
hemodynamic benefits.
Study limitations. Our study has several limitations. It is
retrospective in nature and, therefore, it has all the problems
associated with such analysis. We cannot exclude the
presence of other important predictors of CHB. Certain
“tricks” learned by the operators with experience were
difficult, if not impossible, to standardize. One potentially
important factor that was not analyzed is the detailed
evaluation of the septal artery anatomy by angiography.
Other important data of interest are the vascular territory
distribution by MCE and transient conduction changes on
ECG during the procedure. Although our series is the
largest reported so far, it included a relatively modest
number of patients who required pacemaker placement.
Future prospective studies are needed to validate our
observations.
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